Will create more than 150 new highly skilled jobs to focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world.
mAbxience will manufacture the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme for the treatment of Fabry disease.